F2 Bioscience I 2017 Ltd is 10% Owner at Cullinan Oncology, Inc. (CGEM). They have made 1 open-market trade across 1 company since 2022, most recently 2022-06-23.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CGEM | 616,976 | $12.7M |
Shares reported on the most recent Form 4, priced at the 2022-06-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGEM | SELL | 2022-06-21 | 2022-06-23 | $12.77 | $2.2M | +0.7% | +8.8% | -9.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.